Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/
Accepted 2024-01-24 00:00:00 ET · period of report 2024-01-22 · accession 0000950170-24-007137 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-01-24 | 2024-01-22 | DNTH | MOULDER LEON O JR | Dir | A - Grant | $12.00 | +166.7K | 1.44M | +13% | +$2.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-22 | A | A | 166,667 | $12.00 | 1,436,745 | I See footnote | — | — | (F1) Consists of 166,667 shares of common stock purchased by Tellus BioVentures, LLC ("Tellus") from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). (F2) The securities reported are held of record by Tellus. The Reporting Person may be deemed to have voting and dispositive control over the shares held by Tellus. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. |